MCID: PST011
MIFTS: 50

Pustulosis of Palm and Sole

Categories: Skin diseases

Aliases & Classifications for Pustulosis of Palm and Sole

MalaCards integrated aliases for Pustulosis of Palm and Sole:

Name: Pustulosis of Palm and Sole 12 15
Psoriasis 45 74
Pustular Psoriasis of the Palms and/or Soles 12
Acrodermatitis Continua of Hallopeau 74
Generalized Pustular Psoriasis 74
Pustulosis of Palms and Soles 74
Palmoplantar Pustulosis 12
Acropustulosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4398
MeSH 45 D011565
NCIt 51 C34888
SNOMED-CT 69 27520001
ICD10 34 L40.3

Summaries for Pustulosis of Palm and Sole

MalaCards based summary : Pustulosis of Palm and Sole, also known as psoriasis, is related to psoriatic arthritis and psoriasis 14, pustular, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Pustulosis of Palm and Sole is MRAP (Melanocortin 2 Receptor Accessory Protein), and among its related pathways/superpathways are NF-KappaB Family Pathway and Innate Lymphoid Cell Differentiation Pathways. The drugs Apremilast and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and neutrophil.

Related Diseases for Pustulosis of Palm and Sole

Diseases related to Pustulosis of Palm and Sole via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 757)
# Related Disease Score Top Affiliating Genes
1 psoriatic arthritis 33.5 IL36RN TNF TNFRSF1B
2 psoriasis 14, pustular 32.5 AP1S3 IL36RN
3 impetigo herpetiformis 32.5 CARD14 IL36RN
4 geographic tongue 32.3 IL36RN TNF
5 pustulosis palmaris et plantaris 31.7 AP1S3 CCR6 IL36RN TNF
6 bone inflammation disease 30.9 MRAP TNF TNFRSF1B
7 spondylitis 30.5 TNF TNFRSF1B
8 psoriasis 30.4 CARD14 IL36RN TNF
9 spondyloarthropathy 1 30.2 MRAP TNF TNFRSF1B
10 acrodermatitis 30.2 AP1S3 IL36RN
11 pyoderma 30.1 IL36RN TNF
12 skin disease 30.0 CARD14 IL36RN TNF
13 tenosynovitis 30.0 MRAP TNFRSF1B
14 behcet syndrome 29.9 MRAP TNF TNFRSF1B
15 pityriasis rubra pilaris 29.9 CARD14 IL36RN TNFRSF1B
16 subcorneal pustular dermatosis 29.9 IL36RN TNFRSF1B
17 iritis 29.6 MRAP TNFRSF1B
18 orbital plasma cell granuloma 29.6 MRAP TNFRSF1B
19 pustular psoriasis 29.6 AP1S3 CARD14 IL36RN TNF
20 juvenile rheumatoid arthritis 29.6 TNF TNFRSF1B
21 posterior scleritis 29.5 MRAP TNF
22 guillain-barre syndrome 29.5 TNF TNFRSF1B
23 periodic fever, familial, autosomal dominant 29.4 TNF TNFRSF1B
24 melkersson-rosenthal syndrome 29.3 TNF TNFRSF1B
25 exanthem 29.2 TNF TNFRSF1B
26 panuveitis 29.2 MRAP TNF TNFRSF1B
27 psoriasis 2 12.5
28 psoriasis 15, pustular 12.5
29 psoriasis 10 12.2
30 psoriasis 6 12.2
31 psoriasis 3 12.2
32 psoriasis 9 12.2
33 psoriasis 4 12.1
34 psoriasis 5 12.1
35 psoriasis 8 12.1
36 psoriasis 12 12.1
37 mental retardation and psoriasis 12.1
38 psoriatic juvenile idiopathic arthritis 12.0
39 tranebjaerg svejgaard syndrome 11.8
40 parapsoriasis 11.5
41 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.3
42 chronic recurrent multifocal osteomyelitis 11.3
43 subacute cutaneous lupus erythematosus 11.3
44 psoriasis 1 11.3
45 singleton-merten syndrome 1 11.1
46 systemic onset juvenile idiopathic arthritis 11.1
47 nail disorder, nonsyndromic congenital, 1 11.0
48 singleton-merten syndrome 2 11.0
49 temporomandibular ankylosis 11.0
50 primary cutaneous amyloidosis 11.0

Graphical network of the top 20 diseases related to Pustulosis of Palm and Sole:



Diseases related to Pustulosis of Palm and Sole

Symptoms & Phenotypes for Pustulosis of Palm and Sole

UMLS symptoms related to Pustulosis of Palm and Sole:


pruritus, exanthema, psoriasiform rash

Drugs & Therapeutics for Pustulosis of Palm and Sole

Drugs for Pustulosis of Palm and Sole (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
2 Immunologic Factors Phase 4,Phase 3,Phase 2
3 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
4 Immunosuppressive Agents Phase 4,Phase 3
5 Antirheumatic Agents Phase 4,Phase 3,Phase 2
6 Anti-Infective Agents Phase 4
7 Angiogenesis Inhibitors Phase 4
8 Anti-Inflammatory Agents Phase 4,Phase 3
9 Analgesics Phase 4,Phase 3
10 Peripheral Nervous System Agents Phase 4,Phase 3
11 Angiogenesis Modulating Agents Phase 4
12 Analgesics, Non-Narcotic Phase 4,Phase 3
13 Anti-Bacterial Agents Phase 4
14 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2
15 Immunoglobulins Phase 4,Phase 3,Phase 2
16 Antibodies Phase 4,Phase 3,Phase 2
17
Etanercept Approved, Investigational Phase 3 185243-69-0
18
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
19
tannic acid Approved Phase 3 1401-55-4
20
Infliximab Approved Phase 3 170277-31-3
21
Ustekinumab Approved, Investigational Phase 3 815610-63-0
22 Gastrointestinal Agents Phase 3
23 Dermatologic Agents Phase 3,Phase 2
24
Alitretinoin Approved, Investigational Phase 2 5300-03-8 449171 444795
25 Antineoplastic Agents, Immunological Phase 2
26 Pharmaceutical Solutions Phase 2
27 Interleukin 1 Receptor Antagonist Protein Phase 2

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Apremilast in Palmo-Plantar Psoriasis Completed NCT02400749 Phase 4 Apremilast;Placebo
2 Raptiva in Palm and Sole Psoriasis Terminated NCT00972543 Phase 4
3 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis Completed NCT00353119 Phase 3 Placebo comparator;Etanercept
4 An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis Completed NCT02641730 Phase 3 Guselkumab;Placebo
5 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab Completed NCT02008890 Phase 3
6 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis Completed NCT00629772 Phase 3 Placebo;Infliximab
7 Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis Terminated NCT01091051 Phase 3 Ustekinumab;Placebo (Soduim Chloride)
8 A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis Completed NCT01845987 Phase 2 Placebo;CNTO 1959
9 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients Completed NCT03135548 Phase 2 BI 655130 (low dose);Placebo;BI 655130 (high dose)
10 Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis Completed NCT01245140 Phase 2 alitretinoin;Placebo
11 Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis Completed NCT00301002 Phase 2 Alefacept
12 A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis Recruiting NCT03633396 Phase 2 Placebo
13 Anakinra for Inflammatory Pustular Skin Diseases Recruiting NCT01794117 Phase 2 Anakinra
14 Efficacy Study of TEPSO® Socks in Improving Palmoplantar Pustulosis Terminated NCT01197989 Phase 2
15 Immune Signature of Palmoplantar Pustulosis Completed NCT01780857
16 Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases Recruiting NCT01952275

Search NIH Clinical Center for Pustulosis of Palm and Sole

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: psoriasis

Genetic Tests for Pustulosis of Palm and Sole

Anatomical Context for Pustulosis of Palm and Sole

MalaCards organs/tissues related to Pustulosis of Palm and Sole:

42
Skin, T Cells, Neutrophil, Thyroid, Bone, Tongue, Heart

Publications for Pustulosis of Palm and Sole

Articles related to Pustulosis of Palm and Sole:

(show top 50) (show all 3040)
# Title Authors Year
1
Apremilast as a new treatment option for Acrodermatitis continua of Hallopeau. ( 30623424 )
2019
2
Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report. ( 30800311 )
2019
3
Acrodermatitis continua of Hallopeau response to optimized biological therapy. ( 30865417 )
2019
4
Acrodermatitis Continua of Hallopeau with Psoriatic Arthritis. ( 30936225 )
2019
5
The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review. ( 30938189 )
2019
6
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. ( 30969010 )
2019
7
Nails as immune-privileged sites: a case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast. ( 31025500 )
2019
8
Distinguishing pustular psoriasis and acute generalized exanthematous pustulosis on the basis of plasmacytoid dendritic cells and MxA protein. ( 30667074 )
2019
9
Acute generalized exanthematous pustulosis (AGEP) and psoriasis: what can be learned from co-morbidities. A comparative study. ( 30762030 )
2019
10
Alexithymia and psoriasis: what is the link? ( 30714112 )
2019
11
Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO. ( 30269346 )
2019
12
Serum galectin-9 levels in atopic dermatitis, psoriasis and allergic contact dermatitis: A cross-sectional study. ( 30719989 )
2019
13
Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris. ( 31097934 )
2019
14
Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept. ( 31047699 )
2019
15
The association between the socioeconomic status and anxiety-depression comorbidity in patients with psoriasis: A nationwide population-based study. ( 31054151 )
2019
16
Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. ( 30628634 )
2019
17
A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris. ( 30293440 )
2019
18
Risk for appendicitis, cholecystitis, or diverticulitis in patients with psoriasis. ( 31039227 )
2019
19
Unilateral Remission of Psoriasis Associated with a Spinal Arteriovenous Malformation. ( 30896775 )
2019
20
Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review. ( 31062222 )
2019
21
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. ( 31046809 )
2019
22
Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-center, observational, retrospective, real-life study. ( 31049938 )
2019
23
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. ( 30992173 )
2019
24
A case of Generalized Pustular Psoriasis and arthritis treated with ixekizumab. ( 30998424 )
2019
25
Concordance between the Different Cardiovascular Risk Scores in People with Rheumatoid Arthritis and Psoriasis Arthritis. ( 31001432 )
2019
26
Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. ( 31012051 )
2019
27
Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report ( 31017383 )
2019
28
Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. ( 30963798 )
2019
29
Patients' perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies. ( 30927508 )
2019
30
Serum lipid metabolism in psoriasis and psoriatic arthritis - an update. ( 30899289 )
2019
31
Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. ( 30916734 )
2019
32
Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). ( 30868221 )
2019
33
Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study. ( 30877205 )
2019
34
The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. ( 30879179 )
2019
35
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. ( 30885757 )
2019
36
Twenty Years Without Treatment: A Presentation of Arthritis Mutilans With Psoriasis. ( 30841733 )
2019
37
Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. ( 30861182 )
2019
38
Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis. ( 30811618 )
2019
39
Relapse of psoriatic arthritis in patients with active psoriasis swapped from TNF-α to IL-17A inhibitor. ( 30820927 )
2019
40
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. ( 30792887 )
2019
41
Inflammatory dietary pattern and incident psoriasis, psoriatic arthritis, and atopic dermatitis in women: A cohort study. ( 30797850 )
2019
42
Evaluation of subclinical gut inflammation using faecal calprotectin levels and colonic mucosal biopsy in patients with psoriasis and psoriatic arthritis. ( 30729502 )
2019
43
Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic. ( 30729517 )
2019
44
An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. ( 30733983 )
2019
45
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. ( 30739254 )
2019
46
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. ( 30742092 )
2019
47
Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants. ( 30753645 )
2019
48
Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years. ( 30756253 )
2019
49
Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis. ( 30698628 )
2019
50
Efficacy of secukinumab in psoriasis and psoriatic arthritis: A retrospective multicentre study. ( 30717997 )
2019

Variations for Pustulosis of Palm and Sole

Expression for Pustulosis of Palm and Sole

Search GEO for disease gene expression data for Pustulosis of Palm and Sole.

Pathways for Pustulosis of Palm and Sole

GO Terms for Pustulosis of Palm and Sole

Biological processes related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.67 IL36RN TNF TNFRSF1B
2 cytokine-mediated signaling pathway GO:0019221 9.54 IL36RN TNF TNFRSF1B
3 positive regulation of JNK cascade GO:0046330 9.51 IL36RN TNF
4 positive regulation of interleukin-6 production GO:0032755 9.48 IL36RN TNF
5 humoral immune response GO:0006959 9.46 CCR6 TNF
6 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.43 TNF TNFRSF1B
7 cellular response to lipopolysaccharide GO:0071222 9.43 IL36RN TNF TNFRSF1B
8 extrinsic apoptotic signaling pathway GO:0097191 9.4 TNF TNFRSF1B
9 negative regulation of interleukin-6 production GO:0032715 9.32 IL36RN TNF
10 immune response GO:0006955 9.26 CCR6 IL36RN TNF TNFRSF1B
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.16 TNF TNFRSF1B
12 tumor necrosis factor-mediated signaling pathway GO:0033209 8.8 CARD14 TNF TNFRSF1B

Sources for Pustulosis of Palm and Sole

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....